TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program for cancer treatment; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TGTX
CUSIPN/A
Phone212-554-4484
Debt
Debt-to-Equity RatioN/A
Current Ratio3.68
Quick Ratio3.68
Price-To-Earnings
Trailing P/E Ratio-6.05
Forward P/E Ratio-5.55
P/E GrowthN/A
Sales & Book Value
Annual Sales$150,000.00
Price / Sales6,377.14
Cash FlowN/A
Price / CashN/A
Book Value$0.95 per share
Price / Book12.16
Profitability
EPS (Most Recent Fiscal Year)($1.91)
Net Income$-118,470,000.00
Net Margins-97,412.51%
Return on Equity-177.79%
Return on Assets-128.51%
Miscellaneous
Employees75
Outstanding Shares82,820,000
Market Cap$981.40 million
TG Therapeutics Inc common stock (NASDAQ:TGTX) Frequently Asked Questions
What is TG Therapeutics Inc common stock's stock symbol?
TG Therapeutics Inc common stock trades on the NASDAQ under the ticker symbol "TGTX."
How were TG Therapeutics Inc common stock's earnings last quarter?
TG Therapeutics Inc common stock (NASDAQ:TGTX) announced its quarterly earnings data on Tuesday, August, 7th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by $0.04. The biopharmaceutical company had revenue of $0.04 million for the quarter, compared to analysts' expectations of $0.04 million. TG Therapeutics Inc common stock had a negative net margin of 97,412.51% and a negative return on equity of 177.79%. View TG Therapeutics Inc common stock's Earnings History.
When is TG Therapeutics Inc common stock's next earnings date?
What price target have analysts set for TGTX?
4 equities research analysts have issued 1 year price targets for TG Therapeutics Inc common stock's stock. Their predictions range from $27.00 to $38.00. On average, they anticipate TG Therapeutics Inc common stock's stock price to reach $31.00 in the next twelve months. This suggests a possible upside of 168.4% from the stock's current price. View Analyst Price Targets for TG Therapeutics Inc common stock.
What is the consensus analysts' recommendation for TG Therapeutics Inc common stock?
What are Wall Street analysts saying about TG Therapeutics Inc common stock stock?
Here are some recent quotes from research analysts about TG Therapeutics Inc common stock stock:
- 1. HC Wainwright analysts commented, "Our price target of $38 is based on the net present value of our revenue forecast through 2026, applying a 55% probability of success (POS) for ublituximab in CLL, a 45% POS for umbralisib in 25% POS for both ublituximab and umbralisib in NHL. We use a 4x price/sales multiple, and 1Q18 fully diluted net cash of $1.61/ share to arrive at our price target. Our P/S multiple of 4x is in-line with TG’s peers that range between 2-5x." (8/7/2018)
- 2. According to Zacks Investment Research, "TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York. " (7/26/2018)
- 3. Raymond James analysts commented, "We are maintaining our Strong Buy rating for TG Therapeutics. Today, at the American Academy of Neurology (AAN) 70th Annual Meeting, the company provided an update on the ongoing Phase II study of TG-1101 (ublituximab) in patients with relapsing forms of multiple sclerosis (RMS)." (4/25/2018)
Are investors shorting TG Therapeutics Inc common stock?
TG Therapeutics Inc common stock saw a decrease in short interest in the month of July. As of July 13th, there was short interest totalling 10,718,811 shares, a decrease of 10.0% from the June 29th total of 11,909,287 shares. Based on an average daily volume of 678,772 shares, the days-to-cover ratio is currently 15.8 days. Approximately 15.9% of the shares of the stock are sold short. View TG Therapeutics Inc common stock's Current Options Chain.
Who are some of TG Therapeutics Inc common stock's key competitors?
Some companies that are related to TG Therapeutics Inc common stock include Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC- (GWPH), Madrigal Pharmaceuticals (MDGL), Endo International (ENDP), Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Array Biopharma (ARRY), Opko Health (OPK), Blueprint Medicines (BPMC), Heron Therapeutics (HRTX), Akcea Therapeutics (AKCA), Amicus Therapeutics (FOLD), Ironwood Pharmaceuticals (IRWD) and The Medicines (MDCO).
Who are TG Therapeutics Inc common stock's key executives?
TG Therapeutics Inc common stock's management team includes the folowing people:
- Mr. Michael S. Weiss, Exec. Chairman, CEO & Pres (Age 52)
- Mr. Sean A. Power CPA, CFO, Corp. Sec. & Treasurer (Age 36)
- Jenna Bosco, VP of Investor Relations & Sr. VP of Corp. Communications
- Mr. Adam Waldman, Chief Commercial Officer
Has TG Therapeutics Inc common stock been receiving favorable news coverage?
Media headlines about TGTX stock have been trending somewhat positive recently, Accern reports. Accern identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. TG Therapeutics Inc common stock earned a news and rumor sentiment score of 0.13 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 46.75 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View Recent Headlines for TG Therapeutics Inc common stock.
Who are TG Therapeutics Inc common stock's major shareholders?
TG Therapeutics Inc common stock's stock is owned by a number of of retail and institutional investors. Top institutional investors include RA Capital Management LLC (5.17%), BlackRock Inc. (5.23%), FMR LLC (4.57%), Wells Fargo & Company MN (1.14%), Columbus Circle Investors (0.96%) and Opaleye Management Inc. (0.75%). Company insiders that own TG Therapeutics Inc common stock stock include Laurence N Charney, Sean A Power and William James Kennedy. View Institutional Ownership Trends for TG Therapeutics Inc common stock.
Which major investors are selling TG Therapeutics Inc common stock stock?
TGTX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Senzar Asset Management LLC, Raymond James & Associates, Trexquant Investment LP, Putnam Investments LLC, California Public Employees Retirement System, Columbus Circle Investors and Dupont Capital Management Corp. Company insiders that have sold TG Therapeutics Inc common stock company stock in the last year include Sean A Power and William James Kennedy. View Insider Buying and Selling for TG Therapeutics Inc common stock.
Which major investors are buying TG Therapeutics Inc common stock stock?
TGTX stock was acquired by a variety of institutional investors in the last quarter, including RA Capital Management LLC, Wells Fargo & Company MN, BlackRock Inc., Opaleye Management Inc., Millennium Management LLC, Mycio Wealth Partners LLC, Bank of America Corp DE and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for TG Therapeutics Inc common stock.
How do I buy shares of TG Therapeutics Inc common stock?
Shares of TGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TG Therapeutics Inc common stock's stock price today?
One share of TGTX stock can currently be purchased for approximately $11.55.
How big of a company is TG Therapeutics Inc common stock?
TG Therapeutics Inc common stock has a market capitalization of $981.40 million and generates $150,000.00 in revenue each year. The biopharmaceutical company earns $-118,470,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. TG Therapeutics Inc common stock employs 75 workers across the globe.
How can I contact TG Therapeutics Inc common stock?
TG Therapeutics Inc common stock's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 212-554-4484 or via email at [email protected]
MarketBeat Community Rating for TG Therapeutics Inc common stock (NASDAQ TGTX)
MarketBeat's community ratings are surveys of what our community members think about TG Therapeutics Inc common stock and other stocks. Vote "Outperform" if you believe TGTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TGTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
